Puma Biotechnology (PBYI) Cash from Operations (2010 - 2026)

Puma Biotechnology's Cash from Operations history runs 17 years deep, the most recent figure standing at 15416000.0 for Q1 2026.

• Quarterly Cash from Operations rose 326.8% year-over-year to 15416000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53606000.0 (up 71.35% YoY) and the FY2025 annual result came in at 41802000.0, up 7.41% from the prior year.
• Cash from Operations was 15416000.0 for Q1 2026 at Puma Biotechnology, up from 14419000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 17259000.0 in Q3 2022 and bottomed at 26895000.0 in Q1 2022.
• A 5-year average of 6312823.53 and a median of 10455000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations plunged 18648.65% — and 2025, when it jumped 1271.18%.
• Puma Biotechnology's Cash from Operations stood at 7683000.0 in 2022, then jumped by 36.08% to 10455000.0 in 2023, then soared by 49.28% to 15607000.0 in 2024, then dropped by 7.61% to 14419000.0 in 2025, then gained by 6.91% to 15416000.0 in 2026.
• Business Quant data shows PBYI's Cash from Operations at 15416000.0 in Q1 2026, 14419000.0 in Q4 2025, and 9689000.0 in Q3 2025.